Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 309

1.

Targeting Hypoxia Downstream Signaling Protein, CAIX, for CAR-T Cell Therapy against Glioblastoma.

Cui J, Zhang Q, Song Q, Wang H, Dmitriev P, Sun M, Cao X, Wang Y, Guo L, Indig I, Rosenblum J, Ji C, Cao D, Yang K, Gilbert MR, Yao Y, Zhuang Z.

Neuro Oncol. 2019 Jul 4. pii: noz117. doi: 10.1093/neuonc/noz117. [Epub ahead of print]

PMID:
31276594
2.

Letter: When Less is More: Dexamethasone Dosing for Brain Tumors.

Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY.

Neurosurgery. 2019 Jun 19. pii: nyz186. doi: 10.1093/neuros/nyz186. [Epub ahead of print] No abstract available.

PMID:
31215634
3.

Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT.

Truitt G, Gittleman H, Leece R, Ostrom QT, Kruchko C, Armstrong TS, Gilbert MR, Barnholtz-Sloan JS.

J Neurooncol. 2019 Jun 17. doi: 10.1007/s11060-019-03215-x. [Epub ahead of print]

PMID:
31209773
4.

Reply to 'Assembling the brain trust: the multidisciplinary imperative in neuro-oncology'.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 May 31. doi: 10.1038/s41571-019-0236-y. [Epub ahead of print] No abstract available.

PMID:
31150022
5.

A Transgenic Mouse Model of Pacak⁻Zhuang Syndrome with An Epas1 Gain-of-Function Mutation.

Wang H, Cui J, Yang C, Rosenblum JS, Zhang Q, Song Q, Pang Y, Fang F, Sun M, Dmitriev P, Gilbert MR, Eisenhofer G, Pacak K, Zhuang Z.

Cancers (Basel). 2019 May 14;11(5). pii: E667. doi: 10.3390/cancers11050667.

6.

Challenges to curing primary brain tumours.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ.

Nat Rev Clin Oncol. 2019 Feb 7. doi: 10.1038/s41571-019-0177-5. [Epub ahead of print] Review.

PMID:
30733593
7.

Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial.

Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL.

J Clin Oncol. 2019 Mar 20;37(9):741-750. doi: 10.1200/JCO.18.01207. Epub 2019 Feb 4.

8.

Detection of Metabolic Changes Induced via Drug Treatments in Live Cancer Cells and Tissue Using Raman Imaging Microscopy.

Larion M, Dowdy T, Ruiz-Rodado V, Meyer MW, Song H, Zhang W, Davis D, Gilbert MR, Lita A.

Biosensors (Basel). 2018 Dec 28;9(1). pii: E5. doi: 10.3390/bios9010005.

9.

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism.

Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE.

Clin Cancer Res. 2019 Apr 1;25(7):2305-2313. doi: 10.1158/1078-0432.CCR-18-2572. Epub 2018 Dec 17.

PMID:
30559168
10.

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M.

Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.

PMID:
30514777
11.

Interreader Variability of Dynamic Contrast-enhanced MRI of Recurrent Glioblastoma: The Multicenter ACRIN 6677/RTOG 0625 Study.

Barboriak DP, Zhang Z, Desai P, Snyder BS, Safriel Y, McKinstry RC, Bokstein F, Sorensen G, Gilbert MR, Boxerman JL.

Radiology. 2019 Feb;290(2):467-476. doi: 10.1148/radiol.2019181296. Epub 2018 Nov 27.

PMID:
30480488
12.

Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastoma.

Maraka S, Groves MD, Mammoser AG, Melguizo-Gavilanes I, Conrad CA, Tremont-Lukats IW, Loghin ME, O'Brien BJ, Puduvalli VK, Sulman EP, Hess KR, Aldape KD, Gilbert MR, de Groot JF, Alfred Yung WK, Penas-Prado M.

Cancer. 2019 Feb 1;125(3):424-433. doi: 10.1002/cncr.31811. Epub 2018 Oct 25. Erratum in: Cancer. 2019 Apr 15;125(8):1387.

PMID:
30359477
13.

A Revised Diagnostic Classification of Canine Glioma: Towards Validation of the Canine Glioma Patient as a Naturally Occurring Preclinical Model for Human Glioma.

Koehler JW, Miller AD, Miller CR, Porter B, Aldape K, Beck J, Brat D, Cornax I, Corps K, Frank C, Giannini C, Horbinski C, Huse JT, O'Sullivan MG, Rissi DR, Mark Simpson R, Woolard K, Shih JH, Mazcko C, Gilbert MR, LeBlanc AK.

J Neuropathol Exp Neurol. 2018 Nov 1;77(11):1039-1054. doi: 10.1093/jnen/nly085.

14.

Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade.

Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK.

Neurosurgery. 2019 Apr 1;84(4):945-953. doi: 10.1093/neuros/nyy392.

PMID:
30189044
15.

Heterogeneity within the PF-EPN-B ependymoma subgroup.

Cavalli FMG, Hübner JM, Sharma T, Luu B, Sill M, Zapotocky M, Mack SC, Witt H, Lin T, Shih DJH, Ho B, Santi M, Emery L, Hukin J, Dunham C, McLendon RE, Lipp ES, Gururangan S, Grossbach A, French P, Kros JM, van Veelen MC, Rao AAN, Giannini C, Leary S, Jung S, Faria CC, Mora J, Schüller U, Alonso MM, Chan JA, Klekner A, Chambless LB, Hwang EI, Massimino M, Eberhart CG, Karajannis MA, Lu B, Liau LM, Zollo M, Ferrucci V, Carlotti C, Tirapelli DPC, Tabori U, Bouffet E, Ryzhova M, Ellison DW, Merchant TE, Gilbert MR, Armstrong TS, Korshunov A, Pfister SM, Taylor MD, Aldape K, Pajtler KW, Kool M, Ramaswamy V.

Acta Neuropathol. 2018 Aug;136(2):227-237. doi: 10.1007/s00401-018-1888-x. Epub 2018 Jul 17.

PMID:
30019219
16.

Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma.

Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, Adamstein N, Wang X, Edwards NA, Wu T, Maric D, Giles AJ, Gilbert MR, Quezado M, Nduom EK.

Neurosurgery. 2019 Aug 1;85(2):280-289. doi: 10.1093/neuros/nyy268.

PMID:
30011045
17.

Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy.

Giles AJ, Hutchinson MND, Sonnemann HM, Jung J, Fecci PE, Ratnam NM, Zhang W, Song H, Bailey R, Davis D, Reid CM, Park DM, Gilbert MR.

J Immunother Cancer. 2018 Jun 11;6(1):51. doi: 10.1186/s40425-018-0371-5.

18.

Pharmacologic inhibition of protein phosphatase-2A achieves durable immune-mediated antitumor activity when combined with PD-1 blockade.

Ho WS, Wang H, Maggio D, Kovach JS, Zhang Q, Song Q, Marincola FM, Heiss JD, Gilbert MR, Lu R, Zhuang Z.

Nat Commun. 2018 May 29;9(1):2126. doi: 10.1038/s41467-018-04425-z.

19.

Immunotherapy in CNS cancers: the role of immune cell trafficking.

Ratnam NM, Gilbert MR, Giles AJ.

Neuro Oncol. 2019 Jan 1;21(1):37-46. doi: 10.1093/neuonc/noy084.

PMID:
29771386
20.

Differentiating pseudoprogression from true progression: analysis of radiographic, biologic, and clinical clues in GBM.

Rowe LS, Butman JA, Mackey M, Shih JH, Cooley-Zgela T, Ning H, Gilbert MR, Smart DK, Camphausen K, Krauze AV.

J Neurooncol. 2018 Aug;139(1):145-152. doi: 10.1007/s11060-018-2855-z. Epub 2018 May 16.

PMID:
29767308
21.

Enhancement of mitochondrial biogenesis and paradoxical inhibition of lactate dehydrogenase mediated by 14-3-3η in oncocytomas.

Feng J, Zhang Q, Li C, Zhou Y, Zhao S, Hong L, Song Q, Yu S, Hu C, Wang H, Mao C, Shepard MJ, Hao S, Dominah G, Sun M, Wan H, Park DM, Gilbert MR, Xu G, Zhuang Z, Zhang Y.

J Pathol. 2018 Jul;245(3):361-372. doi: 10.1002/path.5090. Epub 2018 May 29.

PMID:
29704241
22.

Influence of Residual Disease Following Surgical Resection in Newly Diagnosed Glioblastoma on Clinical, Neurocognitive, and Patient Reported Outcomes.

Hall WA, Pugh SL, Wefel JS, Armstrong TS, Gilbert MR, Brachman DG, Werner-Wasik M, Wendland MM, Brown PD, Chao ST, Roof KS, Robins HI, Mehta MP, Curran WJ Jr, Movsas B.

Neurosurgery. 2019 Jan 1;84(1):66-76. doi: 10.1093/neuros/nyy003.

PMID:
29618054
23.

Prognostic value of contrast enhancement and FLAIR for survival in newly diagnosed glioblastoma treated with and without bevacizumab: results from ACRIN 6686.

Boxerman JL, Zhang Z, Safriel Y, Rogg JM, Wolf RL, Mohan S, Marques H, Sorensen AG, Gilbert MR, Barboriak DP.

Neuro Oncol. 2018 Sep 3;20(10):1400-1410. doi: 10.1093/neuonc/noy049.

PMID:
29590461
24.

Clinical decision making in the era of immunotherapy for high grade-glioma: report of four cases.

Ranjan S, Quezado M, Garren N, Boris L, Siegel C, Lopes Abath Neto O, Theeler BJ, Park DM, Nduom E, Zaghloul KA, Gilbert MR, Wu J.

BMC Cancer. 2018 Mar 1;18(1):239. doi: 10.1186/s12885-018-4131-1.

25.

Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database.

Blumenthal DT, Won M, Mehta MP, Gilbert MR, Brown PD, Bokstein F, Brachman DG, Werner-Wasik M, Hunter GK, Valeinis E, Hopkins K, Souhami L, Howard SP, Lieberman FS, Shrieve DC, Wendland MM, Robinson CG, Zhang P, Corn BW.

Neuro Oncol. 2018 Jun 18;20(7):966-974. doi: 10.1093/neuonc/noy017.

26.

Multidose Botulinum Toxin A for Intralaryngeal Injection: A Cost Analysis.

Gilbert MR, Young VN, Smith LJ, Rosen CA.

J Voice. 2019 Mar;33(2):159-161. doi: 10.1016/j.jvoice.2017.11.004. Epub 2018 Jan 4.

PMID:
29307768
27.

Corrigendum to 'Ependymomas arising outside of the central nervous system: A case series and literature review' [J Clin Neurosci 47 (2018) 202-207].

Yust Katz S, Cachia D, Kamiya-Matsuoka C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T.

J Clin Neurosci. 2018 May;51:105. doi: 10.1016/j.jocn.2017.12.011. Epub 2017 Dec 30. No abstract available.

PMID:
29295763
28.

Protein phosphatase 2A inhibition enhances radiation sensitivity and reduces tumor growth in chordoma.

Hao S, Song H, Zhang W, Seldomridge A, Jung J, Giles AJ, Hutchinson MK, Cao X, Colwell N, Lita A, Larion M, Maric D, Abu-Asab M, Quezado M, Kramp T, Camphausen K, Zhuang Z, Gilbert MR, Park DM.

Neuro Oncol. 2018 May 18;20(6):799-809. doi: 10.1093/neuonc/nox241.

29.

Phase I-II clinical trial design: a state-of-the-art paradigm for dose finding.

Yan F, Thall PF, Lu KH, Gilbert MR, Yuan Y.

Ann Oncol. 2018 Mar 1;29(3):694-699. doi: 10.1093/annonc/mdx795.

30.

Novel Targeting of Transcription and Metabolism in Glioblastoma.

Su YT, Chen R, Wang H, Song H, Zhang Q, Chen LY, Lappin H, Vasconcelos G, Lita A, Maric D, Li A, Celiku O, Zhang W, Meetze K, Estok T, Larion M, Abu-Asab M, Zhuang Z, Yang C, Gilbert MR, Wu J.

Clin Cancer Res. 2018 Mar 1;24(5):1124-1137. doi: 10.1158/1078-0432.CCR-17-2032. Epub 2017 Dec 18.

31.

LB-100, a novel Protein Phosphatase 2A (PP2A) inhibitor, sensitizes malignant meningioma cells to the therapeutic effects of radiation.

Ho WS, Sizdahkhani S, Hao S, Song H, Seldomridge A, Tandle A, Maric D, Kramp T, Lu R, Heiss JD, Camphausen K, Gilbert MR, Zhuang Z, Park DM.

Cancer Lett. 2018 Feb 28;415:217-226. doi: 10.1016/j.canlet.2017.11.035. Epub 2017 Dec 2.

32.

Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525.

Shi W, Scannell Bryan M, Gilbert MR, Mehta MP, Blumenthal DT, Brown PD, Valeinis E, Hopkins K, Souhami L, Andrews DW, Tzuk-Shina T, Howard SP, Youssef EF, Lessard N, Dignam JJ, Werner-Wasik M.

Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):38-44. doi: 10.1016/j.ijrobp.2017.08.038. Epub 2017 Sep 4.

33.

Targeting WNT Signaling for Multifaceted Glioblastoma Therapy.

McCord M, Mukouyama YS, Gilbert MR, Jackson S.

Front Cell Neurosci. 2017 Oct 13;11:318. doi: 10.3389/fncel.2017.00318. eCollection 2017. Review.

34.

Ependymomas arising outside of the central nervous system: A case series and literature review.

Yust Katz S, Cachia D, Kamiya-Matsuoka C, Olar A, Theeler B, Penas Prado M, Gilbert MR, Armstrong T.

J Clin Neurosci. 2018 Jan;47:202-207. doi: 10.1016/j.jocn.2017.10.026. Epub 2017 Oct 18. Review. Erratum in: J Clin Neurosci. 2017 Dec 30;:.

PMID:
29054328
35.

Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.

Pratt D, Pittaluga S, Palisoc M, Fetsch P, Xi L, Raffeld M, Gilbert MR, Quezado M.

J Neuropathol Exp Neurol. 2017 Aug 1;76(8):697-708. doi: 10.1093/jnen/nlx051.

36.

MerTK as a therapeutic target in glioblastoma.

Wu J, Frady LN, Bash RE, Cohen SM, Schorzman AN, Su YT, Irvin DM, Zamboni WC, Wang X, Frye SV, Ewend MG, Sulman EP, Gilbert MR, Earp HS, Miller CR.

Neuro Oncol. 2018 Jan 10;20(1):92-102. doi: 10.1093/neuonc/nox111.

37.

Blood-brain barrier pericyte importance in malignant gliomas: what we can learn from stroke and Alzheimer's disease.

Jackson S, ElAli A, Virgintino D, Gilbert MR.

Neuro Oncol. 2017 Sep 1;19(9):1173-1182. doi: 10.1093/neuonc/nox058. Review. Erratum in: Neuro Oncol. 2017 Sep 1;19(9):1285.

38.

An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825.

Gittleman H, Lim D, Kattan MW, Chakravarti A, Gilbert MR, Lassman AB, Lo SS, Machtay M, Sloan AE, Sulman EP, Tian D, Vogelbaum MA, Wang TJC, Penas-Prado M, Youssef E, Blumenthal DT, Zhang P, Mehta MP, Barnholtz-Sloan JS.

Neuro Oncol. 2017 May 1;19(5):669-677. doi: 10.1093/neuonc/now208.

39.

Cardiac glycosides suppress the maintenance of stemness and malignancy via inhibiting HIF-1α in human glioma stem cells.

Lee DH, Cheul Oh S, Giles AJ, Jung J, Gilbert MR, Park DM.

Oncotarget. 2017 Jun 20;8(25):40233-40245. doi: 10.18632/oncotarget.16714.

40.

The p38 signaling pathway mediates quiescence of glioma stem cells by regulating epidermal growth factor receptor trafficking.

Soeda A, Lathia J, Williams BJ, Wu Q, Gallagher J, Androutsellis-Theotokis A, Giles AJ, Yang C, Zhuang Z, Gilbert MR, Rich JN, Park DM.

Oncotarget. 2017 May 16;8(20):33316-33328. doi: 10.18632/oncotarget.16741.

41.

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG.

Blumenthal DT, Gorlia T, Gilbert MR, Kim MM, Burt Nabors L, Mason WP, Hegi ME, Zhang P, Golfinopoulos V, Perry JR, Hyun Nam D, Erridge SC, Corn BW, Mirimanoff RO, Brown PD, Baumert BG, Mehta MP, van den Bent MJ, Reardon DA, Weller M, Stupp R.

Neuro Oncol. 2017 Aug 1;19(8):1119-1126. doi: 10.1093/neuonc/nox025.

42.

Hypoxia in the glioblastoma microenvironment: shaping the phenotype of cancer stem-like cells.

Colwell N, Larion M, Giles AJ, Seldomridge AN, Sizdahkhani S, Gilbert MR, Park DM.

Neuro Oncol. 2017 Jul 1;19(7):887-896. doi: 10.1093/neuonc/now258. Review.

43.

Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair.

Lu Y, Kwintkiewicz J, Liu Y, Tech K, Frady LN, Su YT, Bautista W, Moon SI, MacDonald J, Ewend MG, Gilbert MR, Yang C, Wu J.

Cancer Res. 2017 Apr 1;77(7):1709-1718. doi: 10.1158/0008-5472.CAN-16-2773. Epub 2017 Feb 15.

44.

The VHI-10 and VHI Item Reduction Translations-Are we all Speaking the Same Language?

Gilbert MR, Gartner-Schmidt JL, Rosen CA.

J Voice. 2017 Mar;31(2):250.e1-250.e7. doi: 10.1016/j.jvoice.2016.07.016. Epub 2017 Jan 31. Review.

PMID:
28159457
45.

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas.

Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY.

J Neurooncol. 2017 Mar;132(1):181-188. doi: 10.1007/s11060-016-2357-9. Epub 2017 Jan 23.

46.

Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era: A Correlative Analysis Based on NRG Oncology RTOG 0525.

Bell EH, Pugh SL, McElroy JP, Gilbert MR, Mehta M, Klimowicz AC, Magliocco A, Bredel M, Robe P, Grosu AL, Stupp R, Curran W Jr, Becker AP, Salavaggione AL, Barnholtz-Sloan JS, Aldape K, Blumenthal DT, Brown PD, Glass J, Souhami L, Lee RJ, Brachman D, Flickinger J, Won M, Chakravarti A.

JAMA Oncol. 2017 Jun 1;3(6):784-792. doi: 10.1001/jamaoncol.2016.6020.

47.

Toward Personalized Targeted Therapeutics: An Overview.

Weathers SS, Gilbert MR.

Neurotherapeutics. 2017 Apr;14(2):256-264. doi: 10.1007/s13311-016-0496-5. Review.

48.

Phase III randomized study of radiation and temozolomide versus radiation and nitrosourea therapy for anaplastic astrocytoma: results of NRG Oncology RTOG 9813.

Chang S, Zhang P, Cairncross JG, Gilbert MR, Bahary JP, Dolinskas CA, Chakravarti A, Aldape KD, Bell EH, Schiff D, Jaeckle K, Brown PD, Barger GR, Werner-Wasik M, Shih H, Brachman D, Penas-Prado M, Robins HI, Belanger K, Schultz C, Hunter G, Mehta M.

Neuro Oncol. 2017 Feb 1;19(2):252-258. doi: 10.1093/neuonc/now236. Erratum in: Neuro Oncol. 2017 Feb 1;19(2):e1.

49.

NRG oncology RTOG 0625: a randomized phase II trial of bevacizumab with either irinotecan or dose-dense temozolomide in recurrent glioblastoma.

Gilbert MR, Pugh SL, Aldape K, Sorensen AG, Mikkelsen T, Penas-Prado M, Bokstein F, Kwok Y, Lee RJ, Mehta M.

J Neurooncol. 2017 Jan;131(1):193-199. doi: 10.1007/s11060-016-2288-5. Epub 2016 Oct 21.

50.

Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying).

Ostrom QT, Gittleman H, Kruchko C, Louis DN, Brat DJ, Gilbert MR, Petkov VI, Barnholtz-Sloan JS.

J Neurooncol. 2016 Oct;130(1):31-42. Epub 2016 Jul 14.

Supplemental Content

Loading ...
Support Center